Michiel V. D. H.
- Country
- The Netherlands
- Department
- Medical Oncology
Research Overview
- A Phase 3 Study of MK-2870 Versus Investigator’s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced or Metastatic Urothelial Carcinoma
- Phase 3 Randomized Study of Belzutifan Plus Zanzalintinib Versus Belzutifan Plus Placebo in Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy
- Perioperative Durvalumab plus Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: A Global Open-Label Single-Arm Study
Data & Insights
Has run more than one trial at 90 of 248 partner sites.
Specializations
Advanced Urological Oncology
The investigator specializes in treating advanced urothelial carcinoma and muscle-invasive bladder cancer, with particular emphasis on innovative therapeutic approaches.
- Metastatic Urothelial Cancer Management
- Locally Advanced Bladder Cancer Treatment
- Penile Cancer Therapeutics
Their work encompasses both early-stage and advanced disease states in urological cancers.
Immunotherapy Applications
Focuses on immunotherapy combinations and novel treatment approaches in urological cancers, particularly exploring the potential of various immunotherapeutic agents.
- Checkpoint Inhibitor Therapy
- Combination Immunotherapy Protocols
- Neoadjuvant Immunotherapy Strategies
Expertise extends to integrating immunotherapy with conventional treatment modalities.
Multimodal Treatment Approaches
Specializes in developing combined treatment strategies incorporating chemoradiation therapy and targeted treatments for urological cancers.
- Chemoimmunotherapy Protocols
- Bladder-Preserving Approaches
- Targeted Therapy Integration
Focuses on optimizing treatment sequences and combinations for improved patient outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.